Interdisciplinary Programme of Biomedical Sciences, Graduate School, Chulalongkorn University, Bangkok, Thailand.
Medical Biochemistry Programme, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Malar J. 2022 Aug 30;21(1):250. doi: 10.1186/s12936-022-04267-7.
Glucose 6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PKLR) deficiencies are common causes of erythrocyte haemolysis in the presence of antimalarial drugs such as primaquine and tafenoquine. The present study aimed to elucidate such an association by thoroughly investigating the haematological indices in malaria patients with G6PD and PKLR variants.
Blood samples from 255 malaria patients from Thailand, Myanmar, Laos, and Cambodia were collected to determine haematological profile, G6PD enzyme activity and G6PD deficiency variants. The multivariate analysis was performed to investigate the association between anaemia and G6PD Mahidol, the most common mutation in this study.
The prevalence of G6PD deficiency was 11.1% (27/244) in males and 9.1% (1/11) in female. The MAFs of the G6PD Mahidol and PKLR variants were 7.1% and 2.6%, respectively. Compared with patients with wildtype G6PD after controlling for haemoglobinopathies, G6PD-deficient patients with hemizygous and homozygous G6PD Mahidol exhibited anaemia with low levels of haemoglobin (11.16 ± 2.65 g/dl, p = 0.041). These patients also exhibited high levels of reticulocytes (3.60%). The median value of G6PD activity before treatment (Day 0) was significantly lower than that of after treatment (Day 28) (5.51 ± 2.54 U/g Hb vs. 6.68 ± 2.45 U/g Hb; p < 0.001). Reticulocyte levels on Day 28 were significantly increased compared to that of on Day 0 (2.14 ± 0.92% vs 1.57 ± 1.06%; p < 0.001). PKLR had no correlation with anaemia in malaria patients. The risk of anaemia inpatients with G6PD Mahidol was higher than wildtype patients (OR = 3.48, CI% 1.24-9.75, p = 0.018). Univariate and multivariate analyses confirmed that G6PD Mahidol independently associated with anaemia (< 11 g/dl) after adjusted by age, gender, Plasmodium species, parasite density, PKLR, and haemoglobinopathies (p < 0.001).
This study revealed that malaria patients with G6PD Mahidol, but not with PKLR, had anaemia during infection. As a compensatory response to haemolytic anaemia after malaria infection, these patients generated more reticulocytes. The findings emphasize the effect of host genetic background on haemolytic anaemia and the importance of screening patients for erythrocyte enzymopathies and related mutations prior to anti-malarial therapy.
葡萄糖-6-磷酸脱氢酶(G6PD)和丙酮酸激酶(PKLR)缺乏症是疟原虫药物(如伯氨喹和泰法诺喹)存在时红细胞溶血的常见原因。本研究旨在通过彻底研究 G6PD 和 PKLR 变异体的疟疾患者的血液学指标来阐明这种关联。
从泰国、缅甸、老挝和柬埔寨的 255 名疟疾患者采集血样,以确定血液学特征、G6PD 酶活性和 G6PD 缺乏症变异体。进行多变量分析以研究贫血与本研究中最常见突变 G6PD Mahidol 之间的关系。
男性 G6PD 缺乏症的患病率为 11.1%(27/244),女性为 9.1%(1/11)。G6PD Mahidol 和 PKLR 变异体的 MAF 分别为 7.1%和 2.6%。与携带野生型 G6PD 的患者相比,携带半合子和纯合子 G6PD Mahidol 的 G6PD 缺乏症患者表现出贫血和低血红蛋白水平(11.16±2.65 g/dl,p=0.041)。这些患者的网织红细胞水平也很高(3.60%)。治疗前(第 0 天)G6PD 活性的中位数明显低于治疗后(第 28 天)(5.51±2.54 U/g Hb 与 6.68±2.45 U/g Hb;p<0.001)。第 28 天的网织红细胞水平与第 0 天相比显著增加(2.14±0.92%与 1.57±1.06%;p<0.001)。PKLR 与疟疾患者的贫血无关。与野生型患者相比,G6PD Mahidol 患者发生贫血的风险更高(OR=3.48,CI% 1.24-9.75,p=0.018)。单因素和多因素分析均证实,G6PD Mahidol 在调整年龄、性别、疟原虫种类、寄生虫密度、PKLR 和血红蛋白病后与贫血(<11 g/dl)独立相关(p<0.001)。
本研究表明,患有 G6PD Mahidol 的疟疾患者在感染期间会出现贫血,但没有 PKLR 的疟疾患者则不会。作为疟疾感染后溶血性贫血的代偿反应,这些患者产生了更多的网织红细胞。这些发现强调了宿主遗传背景对溶血性贫血的影响,以及在抗疟治疗前筛查患者红细胞酶病和相关突变的重要性。